The Norwegian Prednisolone in Early Psychosis Study (NorPEPS)
The Norwegian Prednisolone in Early Psychosis Study - NorPEPS. The Role of Immune-modulating Strategies in the Treatment of Psychosis
Sponsor: Haukeland University Hospital
Terminated
Stopped because of COVID 19 pandemic
Other terminated trials from Haukeland University Hospital
Other Cognitive Change trials with similar outcome
A PHASE2 clinical study on Cognitive Change and Immune Suppression, this trial is terminated or withdrawn. The trial is conducted by Haukeland University Hospital and has accumulated 9 data snapshots since 2018. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Feb 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
Jun 2019 — Feb 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Haukeland University Hospital
- Helse Stavanger HF
- St. Olavs Hospital
For direct contact, visit the study record on ClinicalTrials.gov .